CYP21A2: A Potential Drug Target for Obesity, Diabetes and Heart Disease

Target Name: CYP21A2

NCBI ID: G1589

CYP21A2

CYP21A2: A Potential Drug Target for Obesity, Diabetes and Heart Disease

CYP21A2 (steroid 21-monooxygenase), also known as CYP21A2 gene or CYP21A2 enzyme, is a gene that encodes a protein known as 21-hydroxylase. The protein encoded by this gene is a key enzyme in the synthesis of androsterone, which is a natural hormone produced by the adrenal glands. However, in some individuals, the levels of androsterone produced by the adrenal glands may be too high or too low, leading to various health conditions including obesity, diabetes, and heart disease.

Recent studies have identified CYP21A2 as a potential drug target or biomarker for various diseases, including obesity, diabetes, and heart disease. The primary reason for this is the high levels of androsterone produced by individuals with certain genetic variations in the CYP21A2 gene.

The CYP21A2 gene is located on chromosome 10q34 and has been implicated in various diseases, including obesity, diabetes, and heart disease. Studies have shown that individuals with certain genetic variations in the CYP21A2 gene are more likely to be overweight or obese and have a higher risk of developing type 2 diabetes and heart disease.

One of the main functions of the CYP21A2 enzyme is the production of androsterone, which is a natural hormone produced by the adrenal glands. Androsterone plays a crucial role in the body, including the regulation of weight and energy balance. However, individuals with certain genetic variations in the CYP21A2 gene may have reduced or no production of androsterone, leading to an imbalance in the body.

Recent studies have identified a link between the CYP21A2 gene and obesity. Studies have shown that individuals with certain genetic variations in the CYP21A2 gene are more likely to be overweight or obese and have a higher risk of developing type 2 diabetes and heart disease. This is because individuals with these genetic variations may have reduced or no production of androsterone, which can lead to an imbalance in the body and an increased risk of developing obesity and other diseases.

Another potential function of the CYP21A2 enzyme is the production of androsterone, which is a natural hormone produced by the adrenal glands. Androsterone plays a crucial role in the regulation of the body's weight and energy balance. It is well known that obesity is a major risk factor for various diseases, including type 2 diabetes and heart disease. Recent studies have identified the CYP21A2 gene as a potential drug target or biomarker for obesity.

The CYP21A2 gene has also been implicated in the development of type 2 diabetes and heart disease. Studies have shown that individuals with certain genetic variations in the CYP21A2 gene are more likely to have an increased risk of developing type 2 diabetes and heart disease. This is because individuals with these genetic variations may have reduced or no production of androsterone, which can lead to an imbalance in the body and an increased risk of developing type 2 diabetes and heart disease.

In conclusion, CYP21A2 (steroid 21-monooxygenase) is a gene that encodes a protein known as 21-hydroxylase. The protein encoded by this gene is a key enzyme in the synthesis of androsterone, which is a natural hormone produced by the adrenal glands. However, in some individuals, the levels of androsterone produced by the adrenal glands may be too high or too low, leading to various health conditions including obesity, diabetes, and heart disease. Recent studies have identified CYP21A2 as a potential drug target or biomarker for various diseases, including obesity, diabetes, and heart disease, due to its association with the production of androsterone and the risk of various diseases.

Protein Name: Cytochrome P450 Family 21 Subfamily A Member 2

Functions: A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids (PubMed:25855791, PubMed:10602386, PubMed:16984992, PubMed:22014889, PubMed:27721825). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25855791)

The "CYP21A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP21A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets